Loading...
•
Sep 26, 2020
Thermo Fisher Q3 2020 Earnings Report
Thermo Fisher's Q3 2020 earnings significantly increased due to strong revenue growth and pandemic response.
Key Takeaways
Thermo Fisher Scientific reported a strong third quarter in 2020, with revenue increasing by 36% to $8.52 billion and adjusted EPS increasing by 91% to $5.63. The company benefited from $2.0 billion in COVID-19 related revenue and growth in its base business.
Revenue increased 36% to $8.52 billion.
GAAP diluted EPS increased 157% to $4.84.
Adjusted EPS increased 91% to $5.63.
Generated $2.0 billion of COVID-19 related revenue and returned the base business to growth.
Thermo Fisher
Thermo Fisher
Thermo Fisher Revenue by Segment
Revenue by Segment
Life Sciences Solutions Revenue
CapyFin.comAnalytical Instruments Revenue
CapyFin.comSpecialty Diagnostics Revenue
CapyFin.comLaboratory Products and Biopharma Services Revenue
CapyFin.com Forward Guidance
Thermo Fisher is on track to deliver a record year and is positioning the company for an even brighter future.
Positive Outlook
- Launching new products across the company.
- Scaling up production of sample collection products.
- Scaling up production of essential laboratory supplies.
- Increasing pharma services capacity to support new therapies and vaccines.
- Creating a strong foundation for future growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income